• SAHAR AHMED HARBY Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • RASHA A NASSRA Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • JAIDAA F MEKKY Department of Neuropsychiatry, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • SAMIA M ALI Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • CHERINE A ISMAIL assisstant professor, clinical pharmacology department, faculty of medicine, alexandria university


Objective: The principal aim of the present study was to assess the importance of multidrug transporter; P-glycoprotein (P-gp) as a potential therapeutic target in patients with epilepsy. Can P-gp transporter expression modulation by memantine add to the standard antiepileptic drugs (AEDs) response?

Methods: A cohort of 56 epilepsy patients was included in a 4 monthly visits prospective study. Patients were on levetiracetam (LEV) 1000 mg/ day alone or combined with other AEDs. They were randomly assigned into two groups; LEV only group including LEV-treated patients and LEV + memantine group including patients on LEV with add-on oral memantine 10 mg/day until the end of the study. During monthly follow-up visits, therapeutic responses were evaluated for each patient by recording the monthly seizures frequency. Blood samples were drawn from every patient twice (on the first and last visits) for assessment of P-gp mRNA expression level.

Results: Fifty patients completed the study. At the end of 4th month, LEV only group showed a non-significant decrease in P-gp expression and seizure frequency compared to the 1st month, whereas, in LEV + memantine group, P-gp expression was significantly reduced and associated with significant seizure control.

Conclusion: Memantine by hindering P-gp overexpression was apt to enhance LEV efficacy and exhibit a better seizure control.

Keywords: P-glycoprotein, N-methyl d-aspartate receptor, Memantine, Levetiracetam, Epilepsy


1. Xiong J, Mao DA, Liu LQ. Research progress on the role of ABC transporters in the drug resistance mechanism of intractable epilepsy. Biomed Res Int 2015;2015:194541.
2. Kwan P, Arzimanoglou A, Berg A, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 2010;51:1069-77.
3. Tang F, Hartz AM, Bauer B. Drug-resistant epilepsy: Multiple hypotheses, few answers. Front Neurol 2017;8:301.
4. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology 2008;70:54-65.
5. Gidal BE. P-glycoprotein expression and pharmacoresistant epilepsy: Cause or consequence? Epilepsy Curr 2014;14:136-8.
6. Potschka H. Modulating P-glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies? Epilepsia 2010;51:1333-47.
7. West CL, Mealey KL. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. Am J Vet Res 2007;68:1106-10.
8. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008;73:1444-53.
9. Kambli L, Bhatt LK, Oza M, Prabhavalkar K. Novel therapeutic targets for epilepsy intervention. Seizure 2017;51:27-34.
10. Kumar S. Memantine: Pharmacological properties and clinical uses. Neurol India 2004;52:307-9.
11. Vulliemoz S, Iwanowski P, Landis T, Jallon P. Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. Seizure 2009;18:376-8.
12. Suresh SH, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and safety of levetiracetam and carbamazepine as monotherapy in partial seizures. Epilepsy Res Treat 2015;2015:415082.
13. Lancelin F, Franchon E, Kraoul L, Garciau I, Brovedani S, Tabaouti K, et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: Preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit 2007;29:576-83.
14. Marimuthu P, Varadarajan S, Krishnan M, Shanmugam S, Kunjuraman G, Ravinder JR, et al. Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: A double-blind placebo-controlled clinical trial (Phase IIIb pilot study). Ann Indian Acad Neurol 2016;19:344-50.
15. Zafar A, Shahid R, Nazish S, Aljaafari D, Ali Alkhamis F, Alsalman S, et al. Nonadherence to antiepileptic medications: Still a major issue to be addressed in the management of epilepsy. J Neurosci Rural Pract 2019;10:106-12.
16. Peng XX, Tiwari AK, Wu HC, Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer 2012;31:110-8.
17. Zhang JC, Xie F, Yu XH, Deng ZY, Wang Y, Liang P, et al. Expression levels of P-glycoprotein in peripheral blood CD8+T lymphocytes from HIV-1-infected patients on antiretroviral therapy. Int J Mol Med 2014;33:431-40.
18. Kosztyu P, Dolezel P, Vaclavikova R, Mlejnek P. Can the assessment of ABCB1 gene expression predict its function in vitro? Eur J Haematol 2015;95:150-9.
19. Koubeissi M. Neuropathology of the blood-brain barrier in epilepsy: Support to the transport hypothesis of pharmacoresistance. Epilepsy Curr 2013;13:169-71.
20. Rammes G, Danysz W, Parsons C. Pharmacodynamics of Memantine: An update. Curr Neuropharmacol 2008;6:55-78.
21. Mishra A, Goel RK. Chronic 5-HT3 receptor antagonism ameliorates seizures and associated memory deficit in pentylenetetrazole-kindled mice. Neuroscience 2016;339:319-28.
22. Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, et al. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet 2016;99:802-16.
23. Schauwecker PE. Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain. Exp Neurol 2010;224:207-18.
24. Kwan P, Still G, Butler E, Gant T, Meldrum B, Brodie M. Regional expression of multidrug resistance gene in genetically epilepsy-prone rat brain after single ausiogenic sizure. Epilepsia 2002;43:1318-23.
25. Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993;16:165-74.
18 Views | 28 Downloads
How to Cite
HARBY, S. A., R. A. NASSRA, J. F MEKKY, S. M ALI, and C. A ISMAIL. “MEMANTINE, AS A P-GLYCOPROTEIN EXPRESSION MODULATOR, ENHANCES LEVETIRACETAM THERAPEUTIC RESPONSE IN EPILEPTIC PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 5, Mar. 2020, pp. 104-8, doi:10.22159/ajpcr.2020.v13i5.37011.
Original Article(s)